COVID-19 treatment options

在水四方 · 2021-01-03 19:53:48Z

COVID-19 treatment options簡介

來源: 在水四方於 2021-01-03 19:53:48 [檔案] [博客] [舊帖] [給我悄悄話] 本文已被閱讀：次 (4053 bytes)

本文內容已被 [ 在水四方 ] 在 2021-01-03 21:26:38 編輯過。如有問題，請報告版主或論壇管理刪除.

Claims: the information is for your reference only. 
Please follow the advice from the doctors if you experience COVID-19 symptoms.

Treatment for COVID-19:

Proven to be no effect: hydroxychloroquine 羥氯喹 (ref 1), azithromycin 阿奇黴素, also called or Z-Pak (Zithromax, Pfizer)(ref 2).

Proven to have some effects:

1. Compound. Remdesivir (GS-5734), an inhibitor of the viral RNA polymerase, proven to be effective for 
hospitalized patients who only required supplemental oxygen. There was no observed benefit of remdesivir 
in those who were on high-flow oxygen, noninvasive ventilation, neigther for patients with mild to moderate 
conditions (ref 3). However, WHO recommends against the use of remdesivir in COVID-19 patients on 20 November 2020,
no reason is given which is weird (ref 4a). FDA still approves its use based on 3 Nov. notice (ref 4b).

2. Antibody treatment.
Antibody treatments target the spike protein, which the virus utilizes to enter host cells. Eli Lilly’s monoclonal
antibody regimen, bamlanivimab (also known as LY-CoV555),consists of two antibodies directed against the SARS-CoV-2 
spike protein and its receptor binding domain; Regeneron’s products, casirivimab (REGN10933) and imdevimab (REGN10987), 
consists of two antibodies that bind to different regions of the SARS-CoV-2 spike protein receptor binding 
domain (ref 5).However, the supporting evidences based on the clinical trial results for both are not very strong.

Fever reducing for COVID-19: Acetaminophen (Tylenol, DayQuil etc). 服用維生素C要早 + 不宜用 ibuprofen 退燒。

Ref 1: Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.  Nov. 19, 2020. New England Journal of Medicine 383:2030-2040.

Ref 2: Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. Nov. 19, 2020. New England Journal of Medicine 383:2041-2052

Ref 3: Remdesivir for the Treatment of Covid-19 — Final Report. Nov 5, 2020. New England Journal of Medicine 383:1813-1826.

Ref 4a: https://www.who.int/news-room/feature-stories/detail/who-recommends-against-the-use-of-remdesivir-in-covid-19-patients#:~:text=WHO%20recommends%20against%20the%20use%20of%20remdesivir%20in%20COVID%2D19%20patients,-20%20November%202020&text=WHO%20has%20issued%20a%20conditional,other%20outcomes%20in%20these%20patients.
 
Ref 4b: https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/remdesivir/

Ref 5: https://www.idsociety.org/covid-19-real-time-learning-network/therapeutics-and-interventions/monoclonal-antibodies/

更多我的博客文章>>>